Drug
Zilucoplan clinical trials
- studies test it
- 18
- open now
- 4
- in phase 3
- 10
- first study started
- 2017
Keep track of what changes. Save the zilucoplan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
18 studies that test it; most in 2017 (4)
| Year | Studies |
|---|---|
| 2017 | 4 |
| 2019 | 3 |
| 2020 | 4 |
| 2022 | 1 |
| 2024 | 4 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 9
- Phase 3
- 10
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 4
UCB Biopharma SRL (7) · Ra Pharmaceuticals (4) · Merit E. Cudkowicz, MD (2) · Ra Pharmaceuticals, Inc. (2) · University Hospital, Ghent (1) · Amgen (1) · Miriam Freimer (1)
Often tested with
Tested in the same studies.
AZD3241 (1) · CNM-Au8 (1) · Pridopidine (1) · SLS-005 (1) · Fosigotifator sodium tromethamine (1) · Fosigotifator (1) · Evetifator (1) · NUZ-001 (1)
Studies
Open first, then newest update. How each study uses zilucoplan is read from its arms, and is right about nine times in ten.
Testing it · 18
- An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia GravisEnrolling by invitationPhase 3UCB Biopharma SRLNCT06435312Written as Zilucoplan
- A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia GravisRecruitingPhase 2/3UCB Biopharma SRLNCT06055959Written as Zilucoplan
- Zilucoplan for Severe gMG ExacerbationsRecruitingPhase 3Miriam FreimerNCT07215949Written as Zilucoplan®
- A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating WomenRecruitingPhase 1UCB Biopharma SRLNCT06961747Written as Zilucoplan
- Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia GravisCompletedPhase 3UCB Biopharma SRLNCT04225871Written as zilucoplan (RA101495)
- HEALEY ALS Platform Trial - Master ProtocolActive, not recruitingPhase 2/3Merit E. Cudkowicz, MDNCT04297683Written as Zilucoplan
- A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia GravisCompletedPhase 3UCB Biopharma SRLNCT06471361Written as Zilucoplan
- A Study to Evaluate Zilucoplan Injected Subcutaneously Either by a Prefilled Syringe or an Auto-injector in Healthy Adult ParticipantsCompletedPhase 1UCB Biopharma SRLNCT06511076Written as Zilucoplan
- An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 InhibitorsCompletedPhase 3UCB Biopharma SRLNCT05514873Written as zilucoplan (RA101495)
- Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia GravisCompletedPhase 3Ra Pharmaceuticals, Inc.NCT04115293Written as zilucoplan (RA101495)
- Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical StudyTerminatedPhase 2Ra Pharmaceuticals, Inc.NCT03225287Written as Zilucoplan (RA101495)
- Zilucoplan® in Improving Oxygenation, Short-, Longterm Outcome of COVID19 Patients With Acute Hypoxic Respiratory FailureCompletedPhase 2University Hospital, GhentNCT04382755Written as Zilucoplan®
- HEALEY ALS Platform Trial - Regimen A ZilucoplanCompletedPhase 2/3Merit E. Cudkowicz, MDNCT04436497Written as Zilucoplan
- Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH PatientsCompletedPhase 2Ra PharmaceuticalsNCT03078582Written as Zilucoplan (RA101495)
- Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia GravisCompletedPhase 2Ra PharmaceuticalsNCT03315130Written as zilucoplan (RA101495)
- Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Who Have an Inadequate Response to EculizumabCompletedPhase 2Ra PharmaceuticalsNCT03030183Written as Zilucoplan (RA101495)
- Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing MyopathyTerminatedPhase 2Ra PharmaceuticalsNCT04025632Written as zilucoplan
- Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized PatientsCompletedPhase 3AmgenNCT04590586Written as Zilucoplan
Codes
What other systems call zilucoplan · ClinicalTrials.gg INT001712
- MeSH (NLM) C000719268zilucoplanConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) YG391PK0CCZILUCOPLANConfirmed FDA, NLM, Wikidata
- Wikidata Q107340140zilucoplanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C147518ZilucoplanOne source FDA
- DrugBank DB15636One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000719268 | zilucoplan | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | YG391PK0CC | ZILUCOPLAN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q107340140 | zilucoplan | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C147518 | Zilucoplan | One source FDA |
| DrugBank | DB15636 | — | One source Wikidata |
Also registered as zilucoplan sodium (UNII 10R1YC115A).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.